Guselkumab (Tremfya®): A Comprehensive Monograph on a Selective Interleukin-23 Inhibitor for Immune-Mediated Inflammatory Diseases

Executive Summary

Guselkumab, marketed under the brand name Tremfya®, is a first-in-class, fully human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that has emerged as a cornerstone therapy for a range of immune-mediated inflammatory diseases (IMIDs).[1] It functions through the highly selective inhibition of the p19 subunit of interleukin-23 (IL-23), a key cytokine implicated in the pathogenesis of chronic inflammation. This targeted mechanism disrupts the IL-23/T helper 17 (Th17) axis, a critical pathway that drives the inflammatory cascade in conditions such as psoriasis and inflammatory bowel disease.[1]

Initially approved for the treatment of adult patients with moderate-to-severe plaque psoriasis (PsO), Guselkumab's therapeutic applications have expanded significantly based on a robust and ambitious clinical development program. It is now also established for the treatment of active psoriatic arthritis (PsA) and has made a transformative entry into gastroenterology with approvals for moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD).[1]

The evidence base for Guselkumab is distinguished by data from large-scale, pivotal Phase 3 clinical trial programs, including VOYAGE for PsO, DISCOVER for PsA, QUASAR for UC, and GALAXI for CD. A defining feature of this evidence is the inclusion of active comparators in head-to-head trials, which have demonstrated Guselkumab's superiority over established standards of care. Notably, Guselkumab has shown superior efficacy compared to the tumor necrosis factor-alpha (TNF-α) inhibitor adalimumab in plaque psoriasis and, in a landmark finding for the IL-23 inhibitor class, superiority over the IL-12/23 inhibitor ustekinumab for achieving endoscopic endpoints in Crohn's disease.[2]

This monograph provides a comprehensive analysis of Guselkumab, detailing its physicochemical properties, pharmacology, and pharmacokinetic profile. It offers a systematic review of the pivotal clinical trial data across all approved indications, a comparative efficacy analysis that positions it within the current therapeutic landscape, and a thorough examination of its safety profile and practical considerations for its use. The report concludes that Guselkumab represents a significant therapeutic advancement, offering a potent, durable, and targeted treatment option that has reshaped clinical practice and solidified the role of selective IL-23 inhibition in the management of complex IMIDs.

Drug Profile and Physicochemical Properties

A precise understanding of a biologic's identity and fundamental properties is essential for its clinical and scientific evaluation. Guselkumab is well-characterized through a range of standard identifiers and physicochemical parameters.

Identification and Nomenclature

Guselkumab is identified by a consistent set of names and codes across global regulatory and scientific databases, ensuring clarity in research and clinical practice.

• Generic Name: Guselkumab [1]
• Brand Name: Tremfya® [1]
• DrugBank ID: DB11834 [1]
• CAS Number: 1350289-85-8 [2]
• Other Identifiers:
• UNII (Unique Ingredient Identifier): 089658A12D [2]
• KEGG (Kyoto Encyclopedia of Genes and Genomes) ID: D10438 [2]
• Development Code: CNTO1959 [1]

Structural and Chemical Properties

Guselkumab is a protein-based therapeutic agent, classified as a biotech drug. Its structure is that of a whole, fully human monoclonal antibody, which is designed to minimize immunogenicity and optimize its biological function in patients.[1]

• Type: Biotech, Protein-Based Therapy, Monoclonal Antibody (mAb) [1]
• Structure: Guselkumab is a human Immunoglobulin G1 lambda (IgG1λ) isotype. As a biologic, it is produced using recombinant DNA technology in a mammalian cell line, specifically Chinese Hamster Ovary (CHO) cells.[1]
• Molecular Formula: C6402H9864N1676O1994S42 [10]
• Molecular Weight: The molecular weight of Guselkumab is reported with slight variations across different sources, which is typical for large, complex glycoproteins due to post-translational modifications like glycosylation. The reported values range from approximately 143.6 kDa to 145.5 kDa.[3]

The development and manufacturing of Guselkumab are attributed to Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson.[1]

Table 1: Drug Identification and Key Properties

Property	Detail	Source(s)
Generic Name	Guselkumab	1
Brand Name	Tremfya®	1
DrugBank ID	DB11834	1
CAS Number	1350289-85-8	2
Drug Type	Biotech, Monoclonal Antibody	1
Isotype/Source	Human IgG1λ / CHO Cells	1
Molecular Weight	Approx. 144-145 kDa	3
Molecular Formula	C6402H9864N1676O1994S42	10
Developer	Janssen Pharmaceuticals (Johnson & Johnson)	1

Pharmacology and Mechanism of Action

Guselkumab's therapeutic efficacy is rooted in its precise and targeted modulation of the immune system. Its mechanism of action involves the selective inhibition of a key cytokine pathway that is central to the pathophysiology of several chronic inflammatory diseases.

The Interleukin-23/Th17 Axis in Immune-Mediated Disease

The Interleukin-23/T helper 17 (IL-23/Th17) pathway has been identified as a "master" regulatory axis in the pathogenesis of numerous immune-mediated inflammatory diseases, including psoriasis, psoriatic arthritis, and inflammatory bowel disease.[1] IL-23 is a heterodimeric cytokine composed of two subunits: a unique p19 subunit and a p40 subunit that it shares with another cytokine, IL-12. IL-23 is secreted primarily by activated antigen-presenting cells, such as dendritic cells and macrophages, in response to inflammatory stimuli.[1]

The primary function of IL-23 is to act on a specific subset of T lymphocytes known as T helper 17 (Th17) cells. IL-23 promotes the survival, proliferation, and pathogenic effector functions of these cells. Once activated, Th17 cells produce a signature profile of pro-inflammatory cytokines, most notably IL-17A, IL-17F, and IL-22.[1] In the context of psoriasis, these cytokines act directly on keratinocytes in the epidermis, driving the characteristic features of the disease: keratinocyte hyperproliferation (leading to thickened skin), inflammation, and the formation of erythematous, scaly plaques.[1] In inflammatory bowel disease, this same pathway contributes to chronic inflammation and damage to the intestinal mucosa. The over-expression of the IL-23 subunits is a hallmark of these conditions, making the pathway a prime target for therapeutic intervention.[1]

Selective Inhibition of the IL-23p19 Subunit

Guselkumab's mechanism of action is defined by its high specificity. It is a fully human monoclonal antibody that binds with high affinity and selectivity to the p19 subunit of human IL-23.[1] By targeting the unique p19 subunit, Guselkumab effectively neutralizes IL-23, preventing it from binding to its cell surface receptor complex on immune cells like Th17 cells.[1]

This blockade occurs at a critical upstream point in the inflammatory cascade. By inhibiting the initial IL-23 signal, Guselkumab prevents the downstream activation of signaling pathways, such as STAT3 phosphorylation, and consequently suppresses the release of the key effector cytokines IL-17A, IL-17F, and IL-22.[1] The result is a dampening of the aberrant inflammatory response that drives disease pathology.

A crucial aspect of this mechanism is its selectivity. Because Guselkumab targets only the p19 subunit, it does not interfere with the function of IL-12, which shares the p40 subunit but is involved in a different immune pathway (the Th1 pathway). This specificity distinguishes it from first-generation biologics like ustekinumab, which targets the shared p40 subunit and thus inhibits both IL-12 and IL-23.[15] This highly targeted approach, leaving the IL-12 pathway intact, was hypothesized to provide a more refined therapeutic effect. This hypothesis has been validated in head-to-head clinical trials, where the selective inhibition of IL-23 by Guselkumab proved superior to combined IL-12/23 blockade by ustekinumab in Crohn's disease, suggesting that a more focused mechanism can yield greater clinical benefit.[6]

Analysis of the "Dual-Acting" Hypothesis: IL-23 Blockade and CD64 Binding

In communications related to its newer indications in inflammatory bowel disease, Guselkumab has been described as a "dual-acting" monoclonal antibody.[14] This description refers to its primary, well-established function of blocking the IL-23p19 subunit, as well as a secondary property: binding to CD64.[19] CD64, also known as Fc-gamma receptor I (

FcγRI), is a high-affinity receptor for the Fc portion of IgG antibodies and is expressed on the surface of IL-23-producing cells, including monocytes and macrophages.[14]

While this binding has been demonstrated in in vitro laboratory models, its contribution to the overall clinical effect of Guselkumab in humans remains unproven. The developer, Johnson & Johnson, consistently includes the important caveat that "The clinical significance of this finding is not known" in its scientific communications.[16] This distinction is critical. The therapeutic benefit of Guselkumab is robustly and unequivocally supported by extensive preclinical, pharmacodynamic, and clinical data demonstrating the potent effects of IL-23p19 blockade. In contrast, the clinical relevance of CD64 binding is speculative. It is plausible that this secondary interaction could contribute to the drug's activity, for example, by modulating the function of IL-23-producing cells. However, without clinical data to support this, the "dual-acting" terminology should be viewed primarily as a potential differentiator from a marketing perspective rather than an established component of its clinical mechanism. The proven therapeutic value of Guselkumab stems from its highly effective and selective inhibition of the IL-23 cytokine.

Pharmacodynamic Effects: Cytokine Modulation and Cellular Activity

The biological activity of Guselkumab has been quantified through various in vitro and in vivo assays, which confirm its potent and specific pharmacodynamic effects.

Guselkumab exhibits high binding affinity for its target. The dissociation constant (Kd​), a measure of binding strength, has been determined to be 3.3 pmol/L for human IL-23 and 1.9 pmol/L for IL-23 from cynomolgus monkeys, a species often used in preclinical testing.[9]

This strong binding translates into potent functional inhibition. In mouse splenocyte cultures stimulated with IL-23, Guselkumab inhibits the production of the Th17 cytokines IL-17A, IL-17F, and IL-22 with half-maximal inhibitory concentrations (IC50​) ranging from 0.016 to 0.080 nM.[9] Further demonstrating its mechanism, it blocks IL-23-induced STAT3 phosphorylation with an

IC50​ of 102.11 nM.[11] The specificity of the drug is confirmed by the finding that it has no effect on IL-12-mediated production of interferon-gamma (IFNγ).[9]

These preclinical findings are mirrored in clinical studies. Treatment with Guselkumab in patients with psoriasis leads to a significant reduction in the serum levels of IL-17A, IL-17F, and IL-22, confirming that the drug effectively modulates the target pathway in vivo.[1]

Pharmacokinetic Profile

The pharmacokinetic (PK) profile of Guselkumab describes its absorption, distribution, metabolism, and elimination in the body. These properties are characteristic of a human IgG monoclonal antibody and underpin its dosing schedule.

• Absorption: Following a single 100 mg subcutaneous (SC) injection in subjects with psoriasis, Guselkumab is absorbed into the systemic circulation, reaching a mean peak plasma concentration (Cmax​) of 8.09 ± 3.68 mcg/mL. The time to reach this peak concentration (Tmax​) is approximately 5.5 days.[1]
• Distribution: The drug distributes primarily within the vascular and interstitial fluid compartments, as reflected by an apparent volume of distribution (Vd​) of approximately 13.5 L.[1]
• Metabolism and Elimination: Like other endogenous immunoglobulins and therapeutic monoclonal antibodies, Guselkumab is not metabolized by hepatic enzymes (such as the cytochrome P450 system) nor is it eliminated via the kidneys as an intact molecule. Instead, it is expected to be degraded into small peptides and individual amino acids through general protein catabolism pathways that are ubiquitous throughout the body.[1] Consequently, specific clinical trials in patients with renal or hepatic impairment have not been conducted, as significant impacts on its clearance are not anticipated.[22]
• Clearance and Half-Life: The apparent systemic clearance of Guselkumab is approximately 0.516 L/day.[1] It has a long elimination half-life, with a mean of approximately 15 to 18 days in subjects with plaque psoriasis.[1] This extended half-life is a key property that allows for the convenient maintenance dosing interval of every 8 weeks.

Table 2: Summary of Pharmacokinetic Parameters (100 mg SC Dose in Psoriasis Subjects)

Parameter	Unit	Value	Source(s)
Peak Plasma Concentration (Cmax​)	mcg/mL	8.09 ± 3.68	1
Time to Peak Concentration (Tmax​)	days	~5.5	1
Apparent Volume of Distribution (Vd​)	L	13.5	1
Apparent Clearance (CL/F)	L/day	0.516	1
Mean Elimination Half-Life (t1/2​)	days	15 - 18	1

Clinical Efficacy and Pivotal Trial Evidence by Indication

The approval of Guselkumab across its multiple indications is supported by a comprehensive and robust program of Phase 3 clinical trials. These studies have systematically evaluated its efficacy and safety in large, well-defined patient populations, often including active comparators to establish its place in the therapeutic armamentarium. A notable feature of the clinical development strategy has been the aggressive pursuit of superiority claims against existing standards of care, reflecting a high degree of confidence in the molecule's targeted mechanism. This approach has successfully positioned Guselkumab not merely as another therapeutic option, but as a potentially more effective one in specific clinical scenarios.

Plaque Psoriasis (PsO)

Guselkumab was first approved for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, based on the strength of the VOYAGE clinical trial program.[1]

• Pivotal Trials: The cornerstone evidence comes from two large, multicenter, randomized, double-blind trials: VOYAGE 1 (NCT02207231) and VOYAGE 2 (NCT02207244).[2] Both studies compared Guselkumab not only to placebo but also to the widely used TNF-α inhibitor, adalimumab.
• Key Efficacy: The trials consistently demonstrated the superiority of Guselkumab.
• In VOYAGE 1, at the Week 16 primary endpoint, 73.3% of patients treated with Guselkumab achieved at least a 90% improvement from baseline in the Psoriasis Area and Severity Index (PASI 90), a stringent measure of skin clearance. This was significantly higher than the 49.7% of patients who achieved PASI 90 with adalimumab and the 2.9% with placebo.[2]
• Similarly, in VOYAGE 2, at Week 16, the PASI 90 response rate was 70.0% for Guselkumab versus 46.8% for adalimumab.[7] The proportion of patients achieving an Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (minimal) was also significantly higher with Guselkumab (84.1%) compared to adalimumab (67.7%).[7] This superiority was maintained through Week 24 and beyond.
• Specialized Psoriasis Trials: The development program also included trials designed to answer specific clinical questions.
• NAVIGATE (NCT02203032): This study enrolled patients with an inadequate response to the IL-12/23 inhibitor ustekinumab. It showed that switching these difficult-to-treat patients to Guselkumab resulted in significantly greater improvements in skin clearance compared to continuing ustekinumab, demonstrating its efficacy in a biologic-experienced population.[7]
• VISIBLE (NCT05272150): Recognizing the need for data in diverse populations, this ongoing Phase 3b trial is specifically evaluating Guselkumab in patients with skin of color. Initial results at Week 16 are compelling, with Guselkumab showing profound efficacy versus placebo. 74.0% of Guselkumab-treated patients achieved an IGA score of 0/1 compared to 0% of placebo patients, and 57.1% achieved PASI 90 versus just 3.8% for placebo.[26] This trial is crucial for addressing health equity and providing tailored evidence for clinicians treating these populations.

Psoriatic Arthritis (PsA)

Guselkumab's approval for active psoriatic arthritis was based on the DISCOVER program, which established its efficacy in treating both the joint and skin manifestations of the disease.[1]

• Pivotal Trials: The DISCOVER-1 and DISCOVER-2 Phase 3 trials evaluated Guselkumab in adults with active PsA who had an inadequate response to standard therapies.[28] DISCOVER-1 included patients with and without prior biologic experience, while DISCOVER-2 enrolled only biologic-naïve patients.
• Key Efficacy: The primary endpoint in both studies was the American College of Rheumatology 20% improvement (ACR20) response at Week 24. Both Guselkumab dosing regimens (100 mg every 4 weeks and every 8 weeks) demonstrated statistically significant and clinically meaningful improvements in ACR20 response rates compared to placebo.[25] For example, in one study, 52% (q8w) and 59% (q4w) of Guselkumab patients achieved ACR20, versus 22% for placebo.[25]
• Inhibition of Structural Damage (APEX study): A major advancement in the understanding of Guselkumab's role in PsA came from the Phase 3b APEX study. This trial provided definitive evidence that Guselkumab significantly inhibits the progression of structural joint damage. At Week 24, the mean change in the total modified van der Heijde-Sharp (vdH-S) score, which measures joint erosion and space narrowing, was significantly lower in patients treated with Guselkumab compared to placebo.[21] This finding is a critical differentiator, as Guselkumab is the only IL-23 inhibitor to have demonstrated this effect, positioning it as a therapy that not only treats symptoms but may also prevent long-term joint destruction.

Crohn's Disease (CD)

The approval of Guselkumab for moderately to severely active Crohn's disease marked a significant evolution for the IL-23 inhibitor class, establishing its efficacy in a complex gastrointestinal disease with a high unmet need.

• Pivotal Trials: The GALAXI 2 & 3 Phase 3 trials and the GRAVITI (NCT05197049) study formed the basis for approval.[17] The GALAXI program was particularly noteworthy as it included a direct, double-blind, head-to-head comparison against the established IBD therapy, ustekinumab. This design choice underscored the strategy to prove not just efficacy, but superiority.
• Patient Population: The trials enrolled adults with moderately to severely active CD who had previously had an inadequate response or intolerance to conventional therapies or other biologics.[14]
• Key Efficacy: The GALAXI trials successfully demonstrated the superiority of Guselkumab over ustekinumab on key objective endpoints of mucosal healing.
• At Week 48, both Guselkumab maintenance regimens (100 mg q8w and 200 mg q4w) showed statistically significant superiority over ustekinumab on the co-primary endpoints of endoscopic response and clinical remission.[6]
• In the pooled analysis, the endoscopic response rate at Week 48 was 37.1% for ustekinumab, compared to 47.9% for Guselkumab 100 mg q8w and 52.7% for Guselkumab 200 mg q4w. Similar superiority was seen for endoscopic remission and deep remission (a composite of clinical and endoscopic remission).[16] These results provided strong evidence that selective IL-23 inhibition is a more effective strategy than combined IL-12/23 inhibition for achieving gut healing in CD.

Ulcerative Colitis (UC)

Following its success in Crohn's disease, Guselkumab also gained approval for moderately to severely active ulcerative colitis, further solidifying its role in inflammatory bowel disease.

• Pivotal Program: The QUASAR Phase 2b/3 program (EudraCT 2018-004002-25) evaluated Guselkumab in adults with UC who had failed or were intolerant to conventional therapies, other biologics, or Janus kinase (JAK) inhibitors.[17]
• Key Efficacy: The program demonstrated efficacy in both inducing and maintaining remission.
• Induction: In the induction phase, after 12 weeks of treatment with intravenous Guselkumab, 23% of patients achieved clinical remission (as defined by the modified Mayo score) compared to 8% of patients receiving placebo.[25]
• Maintenance: Among patients who responded to induction therapy, subcutaneous Guselkumab was effective as a maintenance treatment. At Week 44, 50% of patients on the higher dose (200 mg q4w) and 45% on the lower dose (100 mg q8w) were in clinical remission, compared to only 19% of those who continued on placebo.[25] This demonstrated the ability of Guselkumab to provide durable, long-term disease control.

Table 3: Key Efficacy Outcomes from Pivotal Phase 3 Trials

Indication	Pivotal Trial(s)	Key Endpoint	Guselkumab Arm Result	Comparator Arm Result	Timepoint
Plaque Psoriasis	VOYAGE 1	PASI 90 Response	73.3%	Adalimumab: 49.7%	Week 16
Psoriatic Arthritis	DISCOVER-2	ACR20 Response	64% (q8w)	Placebo: 33%	Week 24
Crohn's Disease	GALAXI 2 & 3 (Pooled)	Endoscopic Response	47.9% (100mg q8w)	Ustekinumab: 37.1%	Week 48
Ulcerative Colitis	QUASAR	Clinical Remission (Induction)	23%	Placebo: 8%	Week 12

Comparative Efficacy Analysis: Guselkumab in the Therapeutic Landscape

Understanding a drug's value requires placing it in the context of its competitors. Through a series of direct head-to-head trials and indirect comparisons, a clear picture of Guselkumab's relative strengths and differentiators has emerged. This evidence suggests a competitive position that can be characterized as demonstrating superiority over older mechanisms while having a more nuanced, differentiated profile against its contemporary rivals.

Versus TNF-α Inhibition (Adalimumab)

The comparison against adalimumab, a long-standing standard of care in psoriasis, was a central part of Guselkumab's initial development program.

• Source and Finding: The VOYAGE 1 and VOYAGE 2 trials in moderate-to-severe plaque psoriasis provided direct, head-to-head evidence of Guselkumab's superiority.[2] Across multiple timepoints (Weeks 16, 24, and 48), a significantly greater proportion of patients treated with Guselkumab achieved high levels of skin clearance, including PASI 90 and PASI 100 (complete clearance), compared to those treated with adalimumab.[30] A formal meta-analysis of three randomized controlled trials confirmed these findings, solidifying the conclusion that Guselkumab offers better efficacy than adalimumab for psoriasis.[31]
• Biomarker Analysis: A biomarker substudy from the VOYAGE 1 trial provided mechanistic insight into this clinical superiority. While both drugs reduced key inflammatory cytokines, the reductions in serum IL-17A and IL-17F were significantly greater with Guselkumab at multiple timepoints. Furthermore, Guselkumab treatment led to a more profound normalization of the psoriasis-associated gene expression profile in skin lesions compared to adalimumab.[13] This suggests that the targeted blockade of the IL-23 pathway with Guselkumab results in a more complete and durable suppression of the core drivers of psoriasis than the broader blockade of TNF-α.

Versus IL-12/23 Inhibition (Ustekinumab)

The comparison with ustekinumab is particularly insightful, as it pits selective IL-23p19 inhibition against combined IL-12/23 p40 inhibition.

• Source and Finding (Crohn's Disease): The GALAXI 2 & 3 trials provided the most definitive evidence in this comparison.[6] In patients with Crohn's disease, Guselkumab was statistically superior to ustekinumab at Week 48 on multiple objective, endoscopic endpoints, including endoscopic response and remission.[6] This landmark result strongly suggests that for achieving deep mucosal healing in Crohn's disease, selective inhibition of the IL-23 pathway is a more effective strategy than inhibiting both IL-12 and IL-23.
• Source and Finding (Psoriasis): The NAVIGATE trial provided evidence in a different context.[7] In psoriasis patients who were failing to achieve an adequate response with ustekinumab, switching to Guselkumab led to significantly greater skin clearance. This demonstrates Guselkumab's efficacy even in a patient population that is partially or fully resistant to a mechanistically related therapy, highlighting the importance of its more selective action.

Versus IL-17A Inhibition (Ixekizumab, Secukinumab)

The IL-17 inhibitors represent a different, highly effective class of biologics for psoriatic disease. The choice between an IL-23 inhibitor like Guselkumab and an IL-17 inhibitor often involves a trade-off between different attributes.

• Source and Finding (Psoriasis): The IXORA-R trial was a head-to-head study comparing Guselkumab with the IL-17A inhibitor ixekizumab.[32] The results revealed a key difference in the speed of response. Ixekizumab worked significantly faster, with a much higher proportion of patients achieving complete skin clearance (PASI 100) at the 12-week mark (41% for ixekizumab vs. 25% for Guselkumab).[33] However, this gap closed over time. By Week 24, the PASI 100 response rates were statistically non-inferior between the two drugs (50% for ixekizumab vs. 52% for Guselkumab).[32] Ixekizumab did show superior efficacy for clearing nail psoriasis at Week 24.[32] This trial highlights a critical clinical consideration: for patients prioritizing rapid onset of action, an IL-17 inhibitor may be preferred, while for others, the different safety profile and less frequent maintenance dosing of an IL-23 inhibitor like Guselkumab may be more appealing.
• Source and Finding (Psoriatic Arthritis): Direct head-to-head trials in PsA are lacking, but a network meta-analysis provided indirect evidence.[28] This analysis suggested that Guselkumab provides comparable efficacy in improving joint symptoms (as measured by ACR responses) to IL-17A inhibitors, but offers superior efficacy in improving skin symptoms (as measured by PASI responses).[28]

Versus Other Selective IL-23p19 Inhibitors (Risankizumab, Tildrakizumab)

Guselkumab competes within a class of highly selective IL-23p19 inhibitors that also includes risankizumab and tildrakizumab. A significant evidence gap exists here, as there have been no direct head-to-head trials comparing these three drugs.

• Source and Finding: All comparisons currently rely on indirect treatment comparisons (ITCs) or real-world evidence.[36] ITCs, which use a common comparator like placebo or adalimumab to estimate relative efficacy, have generally found no statistically significant differences in skin clearance (e.g., PASI 75/90) between Guselkumab, risankizumab, and tildrakizumab.[38] This suggests that, based on current indirect data, the three drugs have broadly similar efficacy in psoriasis.
• Real-World Evidence: Real-world studies support the high efficacy of all three agents.[36] A large systematic review and meta-analysis of drug survival—a composite measure reflecting long-term effectiveness and tolerability—found that Guselkumab and risankizumab had the highest rates of drug survival among all IL-17 and IL-23 inhibitors studied.[41] This suggests that patients tend to stay on these two therapies longer, which is a strong indicator of their overall value in clinical practice. In the absence of direct comparative efficacy data, differentiation between these agents relies on factors such as dosing frequency, approved indications, and unique data sets, such as Guselkumab's evidence for inhibiting structural joint damage in PsA.[21]

Table 4: Head-to-Head Trial Efficacy Endpoints (Guselkumab vs. Comparators)

Comparator (Class)	Trial Name	Indication	Key Endpoint	Guselkumab Result	Comparator Result	Timepoint	Key Takeaway
Adalimumab (TNF-α)	VOYAGE 1	Plaque Psoriasis	PASI 90 Response	73.3%	49.7%	Week 16	Superiority of Guselkumab
Ustekinumab (IL-12/23)	GALAXI 2 & 3	Crohn's Disease	Endoscopic Response	47.9% (100mg q8w)	37.1%	Week 48	Superiority of Guselkumab
Ixekizumab (IL-17A)	IXORA-R	Plaque Psoriasis	PASI 100 Response	25%	41%	Week 12	Slower onset for Guselkumab
Ixekizumab (IL-17A)	IXORA-R	Plaque Psoriasis	PASI 100 Response	52%	50%	Week 24	Non-inferior efficacy for Guselkumab

Safety, Tolerability, and Risk Management

The safety and tolerability of Guselkumab have been extensively evaluated across a large clinical development program involving thousands of patients and multiple indications. The overall safety profile is consistent with its mechanism of selective immunosuppression and is generally considered manageable.

Comprehensive Adverse Event Profile

The adverse events reported with Guselkumab are well-characterized, with infections being the most common.

• Most Common Adverse Events (>10%): The most frequently reported adverse event across all indications is upper respiratory tract infection (URTI), including nasopharyngitis, affecting up to 14.3% of patients.[2] Overall, infections of any kind are reported in approximately 23% of patients receiving the drug.[22]
• Common Adverse Events (1-10%): Other common adverse events include headache (4.6%), injection site reactions (4.5%), arthralgia (joint pain, 2.7%), elevated liver enzymes (2.6%), diarrhea (1.6%), gastroenteritis (1.3%), and certain infections such as tinea (fungal) infections (1.1%) and herpes simplex infections (1.1%).[2]
• Postmarketing Reports: Since its approval, rare but serious adverse events have been reported. These include serious hypersensitivity reactions, such as anaphylaxis, which can be life-threatening and require immediate medical intervention. Skin reactions like rash have also been reported.[4]

Table 5: Common and Serious Adverse Events Associated with Guselkumab

Frequency Category	Adverse Event	Reported Incidence (if available)	Source(s)
Very Common (>10%)	Upper Respiratory Tract Infections	14.3%	2
	Infections (overall)	23%	22
Common (1-10%)	Headache	4.6%	22
	Injection Site Reactions	4.5%	22
	Arthralgia	2.7%	22
	Elevated Liver Enzymes	2.6%	22
	Diarrhea	1.6%	22
	Gastroenteritis	1.3%	22
	Tinea Infections	1.1%	22
	Herpes Simplex Infections	1.1%	22
Postmarketing (Rare)	Serious Hypersensitivity Reactions (incl. Anaphylaxis)	Not specified	4
	Rash	Not specified	22

Warnings, Precautions, and Contraindications

To ensure safe use, the prescribing information for Guselkumab includes several important warnings, precautions, and a key contraindication.

• Contraindication: Guselkumab is contraindicated in patients with a history of a serious hypersensitivity reaction (e.g., anaphylaxis) to the active substance or to any of its excipients.[4]
• Infections: As an immunosuppressant, Guselkumab may increase the risk of infections. Treatment should not be initiated in patients with any clinically important active infection until the infection resolves or is adequately treated. Patients should be instructed to seek medical advice if they develop signs or symptoms of a significant infection. If a patient develops a serious infection or is not responding to standard treatment, Guselkumab should be discontinued until the infection resolves.[4]
• Pre-treatment Evaluation for Tuberculosis (TB): All patients must be evaluated for TB infection prior to starting Guselkumab. Patients with active TB must not be treated. If latent TB is identified, treatment for TB must be initiated before starting Guselkumab. Patients should be monitored for signs and symptoms of active TB during and after treatment.[4]
• Hepatotoxicity (IBD-specific warning): A critical nuance in the safety profile is the warning regarding potential liver injury, which is specific to the inflammatory bowel disease indications. This warning arose from a report of serious drug-induced liver injury in a subject in a Crohn's disease clinical trial who received a higher-than-recommended induction regimen.[4] Consequently, for patients with UC or CD, it is mandatory to evaluate liver enzymes (transaminases) and bilirubin at baseline, for at least the first 16 weeks of treatment, and periodically thereafter as part of routine management. This specific monitoring is not required for the psoriasis or psoriatic arthritis indications. This indication-specific risk may be related to the higher doses used for IBD induction, a greater prevalence of underlying liver conditions in the IBD population, or a unique interaction with the IBD disease state. It represents a key difference in risk management between the specialties that use this drug.
• Immunizations: The use of live vaccines (e.g., measles, mumps, rubella; BCG) should be avoided in patients being treated with Guselkumab. It is recommended that patients complete all age-appropriate vaccinations according to current guidelines prior to initiating therapy.[4]

Drug-Drug Interaction Potential and Immunogenicity

• Live Vaccines: Co-administration with live vaccines is contraindicated due to the potential for Guselkumab's immunosuppressive effects to increase the risk of infection from the vaccine virus or bacterium.[22]
• CYP450 Substrates: Guselkumab does not interact directly with cytochrome P450 (CYP450) enzymes. However, the levels of these enzymes can be altered by the circulating cytokines present during chronic inflammation. By reducing inflammation and normalizing cytokine levels (such as IL-23), Guselkumab can indirectly affect the metabolism of other drugs that are substrates of CYP450 enzymes. Therefore, caution and therapeutic monitoring are advised when Guselkumab is initiated or discontinued in patients who are also taking CYP450 substrates with a narrow therapeutic index, such as warfarin or cyclosporine.[22]
• Immunogenicity: As with all therapeutic proteins, there is a potential for patients to develop anti-drug antibodies (ADAs) to Guselkumab. The development of ADAs can potentially affect the drug's efficacy or safety. As a fully human monoclonal antibody, Guselkumab is designed to have low immunogenicity.[1] The clinical significance and incidence of ADAs are monitored in clinical trials.

Dosing, Administration, and Practical Considerations

The effective and safe use of Guselkumab requires adherence to specific dosing regimens, which vary by indication, and proper administration techniques. The flexibility of both intravenous (IV) and subcutaneous (SC) formulations allows for tailored treatment approaches, particularly in inflammatory bowel disease.

Approved Dosing Regimens by Indication and Regulatory Body (FDA/EMA)

Guselkumab features distinct induction and maintenance phases for its IBD indications, while the dosing for psoriatic diseases is more straightforward. The regimens are largely harmonized between the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

• Plaque Psoriasis: The recommended dose is 100 mg administered by subcutaneous injection at Week 0 and Week 4, followed by a maintenance dose of 100 mg SC every 8 weeks thereafter.[5]
• Psoriatic Arthritis: The dose is 100 mg SC at Week 0 and Week 4, followed by a maintenance dose of 100 mg SC every 8 weeks. It can be administered alone or in combination with a conventional disease-modifying antirheumatic drug (cDMARD) such as methotrexate.[5] The EMA also notes that for patients at high risk for joint damage, a dose of 100 mg SC every 4 weeks may be considered.[5]
• Ulcerative Colitis:
• Induction: A 200 mg dose administered as an intravenous infusion over at least one hour at Week 0, Week 4, and Week 8.[5]
• Maintenance: Following induction, patients transition to subcutaneous injections. Two options are available: 100 mg SC at Week 16 and every 8 weeks thereafter, or 200 mg SC at Week 12 and every 4 weeks thereafter.[22] The lowest effective dose should be used to maintain response.
• Crohn's Disease: This indication offers the most flexibility, with both IV and SC induction options.
• Induction: Patients can receive either a 200 mg IV infusion at Weeks 0, 4, and 8, or a 400 mg SC dose (administered as two consecutive 200 mg injections) at Weeks 0, 4, and 8.[17]
• Maintenance: Similar to UC, two SC options are available: 100 mg SC at Week 16 and every 8 weeks thereafter, or 200 mg SC at Week 12 and every 4 weeks thereafter.[22]

Table 6: Summary of FDA and EMA Approved Indications and Dosing Regimens

Indication	Phase	Route	Dosing Regimen
Plaque Psoriasis	Induction & Maintenance	SC	100 mg at Weeks 0, 4, then every 8 weeks
Psoriatic Arthritis	Induction & Maintenance	SC	100 mg at Weeks 0, 4, then every 8 weeks (or q4w in high-risk patients per EMA)
Ulcerative Colitis	Induction	IV	200 mg at Weeks 0, 4, and 8
	Maintenance	SC	100 mg q8w (starting at Week 16) OR 200 mg q4w (starting at Week 12)
Crohn's Disease	Induction	IV OR SC	200 mg IV at Weeks 0, 4, 8 OR 400 mg SC at Weeks 0, 4, 8
	Maintenance	SC	100 mg q8w (starting at Week 16) OR 200 mg q4w (starting at Week 12)

Administration Guidelines

Proper handling and administration are crucial for ensuring the drug's efficacy and safety.

• Formulations: Guselkumab is available as a solution for subcutaneous injection in a 100 mg/mL single-dose prefilled syringe or a One-Press patient-controlled injector, and a 200 mg/2mL prefilled pen or syringe. For intravenous use, it is supplied as a 200 mg/20mL single-dose vial for infusion.[22]
• Subcutaneous (SC) Administration: The prefilled syringe or injector should be removed from the refrigerator and allowed to reach room temperature for about 30 minutes before use. Patients can be trained for self-injection into the front of the thighs, the lower abdomen (at least 2 inches away from the navel), or the back of the upper arms (if given by a caregiver). Injection sites that are tender, bruised, red, hard, or affected by psoriasis should be avoided.[5]
• Intravenous (IV) Administration: The 200 mg vial is for professional use only. The required volume is diluted into a 250-mL infusion bag of 0.9% Sodium Chloride to a final concentration of 0.8 mg/mL. The diluted solution is then infused over at least one hour using an infusion set with an in-line, sterile, low-protein-binding 0.2-micron filter. It should not be co-infused with other products.[22]

Use in Special Populations

• Pregnancy and Lactation: There is limited data on the use of Guselkumab in pregnant women. Animal reproduction studies have not indicated harmful effects. As a precaution, women of childbearing potential are advised to use effective contraception during treatment and for at least 12 weeks after the final dose.[5] A pregnancy exposure registry (NCT02103361) exists to collect data on outcomes in pregnant women exposed to Guselkumab.[42]
• Hepatic and Renal Impairment: The pharmacokinetics of Guselkumab have not been studied in patients with hepatic or renal impairment. However, as an IgG monoclonal antibody that is cleared via catabolism, significant effects on its clearance are not expected, and no dose adjustments are currently recommended.[22]
• Pediatric Use: The safety and efficacy of Guselkumab in pediatric patients are under investigation. Clinical trials have been conducted or are ongoing in pediatric populations with psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease to establish appropriate dosing and confirm its benefit-risk profile in these younger age groups.[43]

Emerging Research and Future Directions

The clinical development of Guselkumab continues to evolve beyond its initial approvals. The ongoing research strategy appears focused on two key areas: expanding its use into new immune-mediated diseases and generating data to differentiate it further within its approved indications. This reflects a mature product lifecycle strategy aimed at solidifying its market position by addressing unmet needs and answering critical clinical questions.

Investigational Uses and Ongoing Clinical Trials

The core mechanism of Guselkumab—the targeted inhibition of the IL-23 pathway—lends itself to investigation in a variety of other IMIDs where this pathway is implicated.

• Systemic Sclerosis (Scleroderma): A Phase 2 trial (NCT04683029) evaluating Guselkumab in patients with systemic sclerosis has been completed.[44] This is a significant area of investigation, as scleroderma is a severe autoimmune disease characterized by fibrosis with limited effective treatment options.
• Rarer Dermatologic Conditions: The therapeutic potential of Guselkumab is being explored in less common but severe skin conditions. Studies have been conducted in patients with pyoderma gangrenosum, a neutrophilic dermatosis, and Hailey-Hailey disease, a rare genetic blistering disorder.[43] Positive signals in these conditions could lead to valuable new treatment options for patients with high unmet needs.
• Palmoplantar Psoriasis: A dedicated Phase 3 trial (NCT03998683) has been completed for palmoplantar psoriasis, a localized and often debilitating form of psoriasis that is notoriously difficult to treat.[24] Data from this trial will be crucial for guiding therapy in this specific patient subgroup.

Efficacy in Specific Patient Cohorts

A key part of the ongoing research strategy involves generating data for specific patient populations to demonstrate value and address health disparities.

• VISIBLE Trial (NCT05272150): This ongoing Phase 3b trial is a landmark study designed to formally evaluate the efficacy and safety of Guselkumab in patients with moderate-to-severe plaque psoriasis who self-identify as having skin of color.[26] Historically, clinical trials in dermatology have under-enrolled non-white participants, leading to an evidence gap. The initial results from VISIBLE are robust, showing significant skin clearance and quality of life improvements.[27] This trial is a vital step toward providing high-quality, specific evidence for clinicians treating diverse patient populations and promoting health equity.
• APEX Study (Phase 3b): As previously discussed, the APEX study in psoriatic arthritis has provided a unique and powerful differentiator for Guselkumab.[21] By demonstrating that Guselkumab is the only IL-23 inhibitor proven to significantly inhibit the progression of structural joint damage, this study elevates its role from a symptom-modifying agent to one that can potentially alter the long-term course of the disease and prevent disability.[21] This type of data is highly valued by rheumatologists and payers.

Long-Term Extension Studies and Real-World Evidence

Beyond generating new data, the research program is focused on confirming the long-term durability and safety of Guselkumab.

• Long-Term Extension Studies: Pivotal trials like VOYAGE 2 have long-term extension phases that follow patients for years (up to Week 252, or nearly five years).[45] This provides invaluable data on the maintenance of efficacy over time and the emergence of any rare or delayed adverse events.
• Optimizing Dosing Strategies: Studies like NCT03818035 are exploring more nuanced therapeutic approaches, such as whether "super-responders" (patients who achieve complete clearance) can maintain disease control with a less frequent, de-escalated dosing schedule.[46] This research could lead to more personalized and cost-effective long-term management.
• Real-World Evidence (RWE): A growing body of RWE from patient registries and observational studies is complementing the data from controlled trials. These studies confirm the effectiveness and safety of Guselkumab in routine clinical practice and provide insights into outcomes like drug survival, which serve as a proxy for overall patient satisfaction and long-term success.[36]

Conclusion and Expert Synthesis

Guselkumab (Tremfya®) has firmly established itself as a pivotal therapeutic agent in the management of a broad spectrum of immune-mediated inflammatory diseases. As a highly selective inhibitor of the interleukin-23 p19 subunit, it represents a significant advancement in targeted biologic therapy, with a robust evidence base supporting its use in dermatology, rheumatology, and gastroenterology.

The clinical profile of Guselkumab is defined by several key strengths. Its efficacy in moderate-to-severe plaque psoriasis is not only profound but has been proven superior to the long-standing TNF-α inhibitor standard, adalimumab. In the competitive landscape of inflammatory bowel disease, it achieved a landmark success in the GALAXI trials, demonstrating superiority over the IL-12/23 inhibitor ustekinumab for achieving endoscopic healing in Crohn's disease. This finding validates the hypothesis that a more selective blockade of the IL-23 pathway can yield greater clinical benefit. Furthermore, in psoriatic arthritis, Guselkumab has a unique and compelling evidence base as the only IL-23 inhibitor shown to significantly inhibit the progression of structural joint damage, a crucial long-term outcome for patients. These data, combined with a convenient every-8-week subcutaneous maintenance regimen for psoriatic diseases, underscore its strong value proposition.

The comparative landscape, however, is nuanced. While superior to older biologic classes, its positioning against contemporary rivals requires careful consideration. In psoriasis, the IL-17A inhibitor ixekizumab offers a more rapid onset of action, though Guselkumab achieves comparable levels of skin clearance by 24 weeks. This presents a clear clinical trade-off between speed and other factors like dosing frequency and safety profile. Among its fellow IL-23p19 inhibitors, direct comparative trials are lacking, but indirect and real-world evidence suggests broadly similar efficacy to risankizumab, with both agents demonstrating excellent drug survival rates.

The safety profile of Guselkumab is well-characterized and consistent with its class, with upper respiratory tract infections being the most common adverse event. The risk profile is generally manageable, but requires adherence to standard precautions for immunosuppressive biologics, including pre-treatment screening for tuberculosis and avoidance of live vaccines. A critical point of distinction in its safety profile is the indication-specific warning for hepatotoxicity in patients with inflammatory bowel disease, mandating liver enzyme monitoring for this population—a key practical consideration for prescribing gastroenterologists.

In conclusion, Guselkumab is a cornerstone of modern biologic therapy. It has reshaped treatment algorithms by providing a highly effective, durable, and targeted option that has, in many cases, raised the bar for therapeutic success. Its development program has strategically and successfully demonstrated its value against previous standards of care, and its ongoing research continues to refine its clinical role and expand its potential benefits. For clinicians and patients navigating the complexities of chronic immune-mediated disease, Guselkumab stands as a leading therapeutic choice, backed by powerful evidence of its ability to control disease and improve quality of life.

Works cited

1. Guselkumab: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed July 31, 2025, https://go.drugbank.com/drugs/DB11834
2. Guselkumab - Wikipedia, accessed July 31, 2025, https://en.wikipedia.org/wiki/Guselkumab
3. Guselkumab (Anti-IL-23) Interleukins inhibitor | Read Reviews & Product Use Citations - Selleck Chemicals, accessed July 31, 2025, https://www.selleckchem.com/products/guselkumab--anti-il-23.html
4. Official Healthcare Professional Website | TREMFYA® (guselkumab ..., accessed July 31, 2025, https://www.tremfyahcp.com/
5. Tremfya, INN-guselkumab - European Medicines Agency, accessed July 31, 2025, https://www.ema.europa.eu/en/documents/product-information/tremfya-epar-product-information_en.pdf
6. Guselkumab Demonstrates Superior Efficacy in Landmark Clinical ..., accessed July 31, 2025, https://www.mountsinai.org/about/newsroom/2025/guselkumab-demonstrates-superior-efficacy-in-landmark-clinical-trials-and-offers-new-hope-to-crohns-disease-patients
7. New Results From Second Phase 3 Study Show Significant Efficacy of Guselkumab and Superiority Versus Humira® in Treatment of Moderate to Severe Plaque Psoriasis, accessed July 31, 2025, https://www.jnj.com/media-center/press-releases/new-results-from-second-phase-3-study-show-significant-efficacy-of-guselkumab-and-superiority-versus-humira-in-treatment-of-moderate-to-severe-plaque-psoriasis
8. Guselkumab |CAS 1350289-85-8|DC Chemicals, accessed July 31, 2025, https://www.dcchemicals.com/product_show-guselkumab.html
9. Guselkumab | IL Receptor - TargetMol, accessed July 31, 2025, https://www.targetmol.com/compound/guselkumab
10. CAS 1350289-85-8 guselkumab - BOC Sciences, accessed July 31, 2025, https://www.bocsci.com/guselkumab-cas-1350289-85-8-item-7061.html
11. Guselkumab - Product Data Sheet, accessed July 31, 2025, https://file.medchemexpress.com/batch_PDF/HY-P9931/Guselkumab-DataSheet-MedChemExpress.pdf
12. Tremfya (guselkumab) FDA Approval History - Drugs.com, accessed July 31, 2025, https://www.drugs.com/history/tremfya.html
13. Guselkumab vs adalimumab for moderate-to-severe plaque psoriasis: A biomarker analysis from the VOYAGE 1 trial - PsOPsA Hub, accessed July 31, 2025, https://psoriasis-hub.com/medical-information/guselkumab-vs-adalimumab-for-moderate-to-severe-plaque-psoriasis-a-biomarker-analysis-from-the-voyage-1-trial
14. U.S. FDA approves TREMFYA® (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn's disease, accessed July 31, 2025, https://www.jnj.com/media-center/press-releases/u-s-fda-approves-tremfya-guselkumab-the-first-and-only-il-23-inhibitor-offering-both-subcutaneous-and-intravenous-induction-options-for-adult-patients-with-moderately-to-severely-active-crohns-disease
15. Guselkumab vs Adalimumab in Plaque Psoriasis - HCPLive, accessed July 31, 2025, https://www.hcplive.com/view/guselkumab-vs-adalimumab-plaque-psoriasis
16. TREMFYA® (guselkumab) demonstrates superiority versus STELARA® (ustekinumab) in Phase 3 Crohn's disease program, accessed July 31, 2025, https://www.jnj.com/media-center/press-releases/tremfya-guselkumab-demonstrates-superiority-versus-stelara-ustekinumab-in-phase-3-crohns-disease-program
17. FDA Approves Guselkumab for Adult Patients With Crohn Disease, accessed July 31, 2025, https://www.ajmc.com/view/fda-approves-guselkumab-for-adult-patients-with-crohn-disease
18. European Commission approves TREMFYA® (guselkumab), the first dual-acting IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn's disease, accessed July 31, 2025, https://innovativemedicine.jnj.com/emea/newsroom/european-commission-approves-tremfya-guselkumab-the-first-dual-acting-il-23-inhibitor-offering-both-subcutaneous-and-intravenous-induction-options-for-adult-patients-with-moderately-to-severely-active-crohns-disease
19. TREMFYA® (guselkumab) receives European Commission approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory bowel disease, accessed July 31, 2025, https://innovativemedicine.jnj.com/emea/newsroom/tremfya-guselkumab-receives-european-commission-approval-for-adults-with-moderately-to-severely-active-ulcerative-colitis-strengthening-johnson-johnsons-leadership-in-inflammatory-bowel-disease
20. European Commission approves TREMFYA® (guselkumab), the first dual-acting IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn's disease - GlobeNewswire, accessed July 31, 2025, https://www.globenewswire.com/news-release/2025/05/07/3075821/0/en/European-Commission-approves-TREMFYA-guselkumab-the-first-dual-acting-IL-23-inhibitor-offering-both-subcutaneous-and-intravenous-induction-options-for-adult-patients-with-moderatel.html
21. New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor ..., accessed July 31, 2025, https://www.jnj.com/media-center/press-releases/new-data-show-tremfya-guselkumab-is-the-only-il-23-inhibitor-proven-to-significantly-inhibit-progression-of-joint-structural-damage-in-active-psoriatic-arthritis
22. Tremfya (guselkumab) dosing, indications, interactions, adverse ..., accessed July 31, 2025, https://reference.medscape.com/drug/tremfya-guselkumab-1000164
23. www.jnj.com, accessed July 31, 2025, https://www.jnj.com/media-center/press-releases/u-s-fda-approves-tremfya-guselkumab-the-first-and-only-il-23-inhibitor-offering-both-subcutaneous-and-intravenous-induction-options-for-adult-patients-with-moderately-to-severely-active-crohns-disease#:~:text=ABOUT%20TREMFYA%C2%AE%20(guselkumab)&text=TREMFYA%C2%AE%20is%20a%20prescription,adults%20with%20active%20psoriatic%20arthritis.
24. Guselkumab Completed Phase 3 Trials for Psoriasis Treatment | DrugBank Online, accessed July 31, 2025, https://go.drugbank.com/drugs/DB11834/clinical_trials?conditions=DBCOND0013339&phase=3&purpose=treatment&status=completed
25. Tremfya | European Medicines Agency (EMA), accessed July 31, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/tremfya
26. Study Details | Study of Guselkumab in Skin of Color Participants ..., accessed July 31, 2025, https://www.clinicaltrials.gov/study/NCT05272150
27. Guselkumab for Moderate to Severe Psoriasis Across All Skin Tones: Cohort A of the VISIBLE Randomized Clinical Trial - PubMed, accessed July 31, 2025, https://pubmed.ncbi.nlm.nih.gov/40560559/
28. Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis | Rheumatology | Oxford Academic, accessed July 31, 2025, https://academic.oup.com/rheumatology/article/60/5/2109/6222946
29. TREMFYA® (guselkumab) demonstrates superiority versus STELARA® (ustekinumab) in Phase 3 Crohn's disease program - PR Newswire, accessed July 31, 2025, https://www.prnewswire.com/news-releases/tremfya-guselkumab-demonstrates-superiority-versus-stelara-ustekinumab-in-phase-3-crohns-disease-program-302151294.html
30. Guselkumab Superior to Humira in Phase III Trial - BioPharm International, accessed July 31, 2025, https://www.biopharminternational.com/view/guselkumab-superior-humira-phase-iii-trial-0
31. Efficacy of guselkumab compared with adalimumab for psoriasis: a meta-analysis of randomized controlled studies - PMC, accessed July 31, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9704462/
32. (PDF) A Head‐to‐Head Comparison of Ixekizumab Versus Guselkumab in Patients with Moderate‐to‐Severe Plaque Psoriasis: 24‐Week Efficacy and Safety Results from a Randomised, Double‐Blinded Trial - ResearchGate, accessed July 31, 2025, https://www.researchgate.net/publication/344081759_A_Head-to-Head_Comparison_of_Ixekizumab_Versus_Guselkumab_in_Patients_with_Moderate-to-Severe_Plaque_Psoriasis_24-Week_Efficacy_and_Safety_Results_from_a_Randomised_Double-Blinded_Trial
33. Journal Club Review: Ixekizumab vs. Guselkumab in Plaque Psoriasis (12-Week Trial Results) - YouTube, accessed July 31, 2025, https://www.youtube.com/watch?v=-pqdNF4pnIo
34. A head‐to‐head comparison of ixekizumab vs. guselkumab in ..., accessed July 31, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8246960/
35. head comparison of ixekizumab vs. guselkumab in patients with moderate‐, accessed July 31, 2025, https://academic.oup.com/bjd/article-pdf/184/6/1047/47953587/bjd1047.pdf
36. Guselkumab, Risankizumab, and Tildrakizumab demonstrate parallel effectiveness and safety in psoriasis treatment: a head-to-head comparative study in real clinical practice, accessed July 31, 2025, https://www.anaisdedermatologia.org.br/pt-guselkumab-risankizumab-tildrakizumab-demonstrate-parallel-articulo-S0365059624001740
37. Full article: Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis - Taylor & Francis Online, accessed July 31, 2025, https://www.tandfonline.com/doi/full/10.1080/09546634.2022.2133531
38. A Systematic Literature Review and Bucher Indirect Comparison: Tildrakizumab versus Guselkumab | Published in Journal of Health Economics and Outcomes Research, accessed July 31, 2025, https://jheor.org/article/13671-a-systematic-literature-review-and-bucher-indirect-comparison-tildrakizumab-versus-guselkumab
39. Systematic review and indirect treatment comparison of the efficacy of tildrakizumab vs guselkumab or risankizumab for the treat - Evidinno Outcomes Research Inc., accessed July 31, 2025, https://evidinno.com/wp-content/uploads/2024/10/CANADI1.pdf
40. Management of Plaque Psoriasis: A Review and Comparison of IL ..., accessed July 31, 2025, https://www.emjreviews.com/dermatology/article/management-of-plaque-psoriasis-a-review-and-comparison-of-il-23-inhibitors/
41. Guselkumab, Risankizumab Boast Longest Drug Survival Among IL-17, IL-23 Inhibitors, accessed July 31, 2025, https://www.hcplive.com/view/guselkumab-risankizumab-boast-longest-drug-survival-among-il-17-il-23-inhibitors
42. Psoriatic Arthritis Recruiting Phase Trials for Guselkumab (DB11834) | DrugBank Online, accessed July 31, 2025, https://go.drugbank.com/indications/DBCOND0028320/clinical_trials/DB11834?status=recruiting
43. What clinical trials have been conducted for Guselkumab?, accessed July 31, 2025, https://synapse.patsnap.com/article/what-clinical-trials-have-been-conducted-for-guselkumab
44. Scleroderma, Systemic Completed Phase 2 Trials for Guselkumab (DB11834) - DrugBank, accessed July 31, 2025, https://go.drugbank.com/indications/DBCOND0028174/clinical_trials/DB11834?phase=2&status=completed
45. A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment (VOYAGE 2) - ClinicalTrials.gov, accessed July 31, 2025, https://www.clinicaltrials.gov/study/NCT02207244
46. A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis (GUIDE) - ClinicalTrials.gov, accessed July 31, 2025, https://clinicaltrials.gov/study/NCT03818035